StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

Research analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued on Friday. The firm set a “hold” rating on the stock.

Aspira Women’s Health Price Performance

AWH opened at $0.70 on Friday. The company has a market capitalization of $11.67 million, a PE ratio of -0.58 and a beta of 1.39. The business has a 50-day moving average of $0.83 and a 200-day moving average of $1.14. Aspira Women’s Health has a fifty-two week low of $0.67 and a fifty-two week high of $5.65.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.